Gujarat Kidney Link 
Allotment
The Gujarat Kidney IPO is a book-built issue of ₹250.80 crores, consisting entirely of a fresh issue of 2.20 crore shares, valued at ₹250.80 crore. The IPO will open for subscription on December 22, 2025, and close on December 24, 2025. The allotment for the IPO is expected to be finalized by December 26, 2025, and the listing on BSE and NSE is tentatively scheduled for December 30, 2025.
The price band for the IPO is set between ₹108.00 and ₹114.00 per share. The lot size for retail investors is 128 shares, requiring a minimum investment of ₹14,592 (based on the upper price band).
For SNI (Small and Medium Investors), the lot size is 14 lots (1,792 shares), totaling ₹2,04,288, while for BNI (Big and HNI Investors), the lot size is 69 lots (8,832 shares), amounting to ₹10,06,848. The book-running lead manager for the issue is Nirbhay Capital Services Pvt. Ltd., and the registrar of the issue is MUFG Intime India Pvt. Ltd.. For more detailed information, refer to the Gujarat Kidney IPO RHP
₹114
0%
Open
₹114
HIgh - Low
₹114
Previous Close
₹114
Total Traded Value
0
52 Weeks High
₹114
52 Weeks Low
₹114
Updates On
Dec 15, 2025
IPO. Open
Dec 22, 2026
IPO. Close
Dec 24, 2026
IPO. Price
₹114.00
IPO Market price
₹898.81 Cr
IPO Details
| IPO Date | 30 Dec |
| IPO Listing Date | 30 Dec |
| IPO Face Value | ₹2 Per Equity Share |
| IPO Price Range | ₹114.00 |
| IPO Issue Size | 2,20,00,000 shares |
| IPO Sale Type | Fresh Capital |
| Employee Discount | - |
| IPO Issue Type | Book Build Issue |
| IPO Listing | BSE, NSE Platform |
| Share Holding Pre Issue | 5,68,43,250 shares |
IPO Timeline
| IPO Open Date | 22 Dec |
| IPO Close Date | 24 Dec |
| IPO Allotment (Tentative) | 26 Dec |
| Refunds | 29 Dec |
| Credit to Demat Account | 29 Dec |
| IPO Listing Date | 30 Dec |
IPO Reservation
| Category | Offer |
|---|---|
| QIB Shares Offered | Not less than 75% of the Issue |
| NII (HNI) Shares Offered | Not more than 15% of the Issue |
| Retail Shares Offered | Not more than 10% of the Issue |
IPO Lot Size
Investors can bid for a minimum of 128 shares and in multiples thereof.
| Application | Lots | Share | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 128 | ₹14,592 |
| Retail (Max) | 13 | 1664 | ₹1,89,696 |
| S-HNI (Min) | 14 | 1,792 | ₹2,04,288 |
| S-HNI (Max) | 68 | 8,704 | ₹9,92,256 |
| B-HNI (Min) | 69 | 8,832 | ₹10,06,848 |
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) is a prominent provider of multispeciality healthcare services, offering both secondary and tertiary care across various locations in Gujarat, India.
The company operates seven multispeciality hospitals and four pharmacies, with a total bed capacity of 490 beds. Of these, 455 beds are approved, and 340 beds are operational.
The company’s hospitals include:
Gujarat Kidney and Superspeciality Hospital (Vadodara)
Gujarat Multispeciality Hospital (Godhra)
Raj Palmland Hospital Private Limited (Bharuch)
M/s. Surya Hospital and ICU (Borsad)
Gujarat Surgical Hospital (Vadodara)
Ashwini Medical Centre (Anand)
Additionally, the company operates Ashwini Medical Store in Anand.
Services Offered:
Secondary Care Services: General and surgical treatments.
Tertiary Care Services: Super speciality surgical procedures.
The Gujarat Superspeciality Hospital provides advanced medical care in several specialties, including:
Internal Medicine
General Surgery
Minimally Invasive Procedures
Orthopaedics & Trauma Treatment
Joint Replacement Surgery
Obstetrics & Gynaecology
Respiratory Failure
Non-interventional Cardiology
Diabetology
Anaesthesiology
As of June 30, 2025, the company employs a team of 89 doctors, 332 nurses, and **338 other staff members.
Competitive Strengths:
Leadership in Renal Sciences, with specialized sub-superspecialties in urology.
Asset-light business model, focusing on the central region of Gujarat.
Strong capability to attract and retain skilled and experienced medical professionals.
A proven track record of operational success and consistent financial growth.
Company Financials (Consolidated)
| Assets | 61.59 | 55.34 | 20.53 |
| Total Income | 15.27 | 40.4 | 5.48 |
| Profit After Tax | 5.4 | 9.5 | 1.71 |
| EBITDA | 8.63 | 16.55 | 1.95 |
| NET Worth | 30.56 | 25.71 | 10.8 |
| Reserves and Surplus | 19.42 | 14.57 | 10.6 |
| Total Borrowing | 4.03 | 3.88 | 1.94 |
Key Performance Indicator (KPI)
| ROE | 36.61% |
| ROCE | 37.65% |
| Debt/Equity | - |
| RoNW | 36.61% |
| PAT Margin | 23.61% |
| EBITDA Margin | 41.12% |
| Price to Book Value | 22.62 |
IPO Objects of the Issue
| S.No. | Objects of the ipo Resources Detail | IPO Amount |
|---|---|---|
| 1 | Funding capital expenditure requirements for the purchase of equipment/machineries | 30.1 |
| 2 | To meet out the expenses of Working Capital Requirement | - |
| 3 | To meet out the General Corporate Purposes; | 87.44 |
| 4 | Offer for Sale (OFS) | - |
Contact Details
Gujarat Kidney and Super Speciality Limited
Plot No. 1, City Sarve No. 1537/A,
Jetalpur Road, Gokak Mill Compound,
Alkapuri, Vadodara – 390 020, Gujarat
Phone: +91 265 298 4800
Email: info@gujaratsuperspecialityhospital.com
Website: https://www.gujaratsuperspecialityhospital.com/
Detail Registrar
IPO Registrar
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: gujaratkidney.ipo@in.mpms.mufg.com
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
The Gujarat Kidney IPO will open on December 22, 2025, and close on December 24, 2025, with tentative allotment on December 26, 2025.
The IPO price band is ₹108 to ₹114 per share. Retail investors must apply for at least 128 shares, requiring a minimum investment of ₹14,592 at the upper band.
Gujarat Kidney shares are proposed to be listed on both BSE and NSE, with a tentative listing date scheduled around December 29–30, 2025.
IPO proceeds will be used for hospital acquisitions, setting up a new hospital, purchasing robotics equipment, repaying borrowings, and supporting inorganic growth and general corporate purposes.
The company reported strong growth, with revenue increasing by 637% and profit after tax rising by 454% in FY2025, reflecting rapid expansion and improved operational performance.
Compare:
